Back HCV Populations

HCV Populations

People on Opiate Substitution Therapy Respond Well to AbbVie Hepatitis C Treatment

Nearly all genotype 1 hepatitis C patients with a history of injection drug use who were on stable opiate substitution therapy with methadone or buprenorphine were cured using AbbVie's Viekira Pak regimen plus ribavirin for 12 weeks, according to a Phase 2 study described in the August 2015Journal of Hepatology. No interactions were seen between opiate substitution therapy and the hepatitis C drugs.

alt

Read more:

AASLD 2014: Young Drug Injectors on Opioid Agonist Therapy Have Lower Risk of HCV Infection

Young people who inject drugs (PWID) who undergo opioid agonist maintenance therapy with methadone or buprenorphine have more than a 60% reduction in their risk of acquiring hepatitis C virus (HCV) over time, compared to those with no substance use treatment, according to a study presented Monday at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. Findings were also published in the October 27 edition of JAMA Internal Medicine.

alt

Read more:

EACS 2013: HCV Reinfection Common Among HIV Positive Gay Men in Europe

A study found that 18% of HIV positive men acquired hepatitis C virus (HCV) a second time after clearing the virus, with some having third and fourth infections as well, according to findings from the European AIDS Treatment Network presented at the 14th European AIDS Conference this month in Brussels.

alt

Read more:

Opioid Maintenance Therapy Linked to Lower Hepatitis C Rates for People Who Inject Drugs

Young drug injectors who undergo opioid agonist maintenance therapy using buprenorphine or methadone have a lower likelihood of becoming infected with hepatitis C virus (HCV) than those who continue injecting or use other types of substance use treatment, according to a study published in the October 27 edition of JAMA Internal Medicine.

alt

Read more:

Hepatitis C Prevention and Management for People Who Inject Drugs

People who inject drugs can benefit from hepatitis C prevention efforts and antiviral treatment, but comprehensive programs may be needed to help overcome a variety of challenges, according to a special supplement of Clinical Infectious Diseases entitled "Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward." The International Network on Hepatitis in Substance Users is holding its biennial symposium this week in Munich.

alt

Read more: